Navigation Links
Callisto Reports on Second-Quarter 2007 Milestones
Date:8/19/2007

ute leukemia, a currently incurable blood cancer. L-Annamycin is currently in a Phase I clinical trial in adult relapsed or refractory acute lymphocytic leukemia, and in a Phase I clinical trial in children and young adults with refractory or relapsed acute lymphocytic leukemia or acute myelogenous leukemia. L- Annamycin, a member of the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including potential activity against multi- drug resistant tumors and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Callisto also has a proprietary drug Guanilib in preclinical development for gastro- intestinal disorders. Callisto has exclusive worldwide licenses from Genzyme Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L-Annamycin, respectively. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. More information is available at http://www.callistopharma.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Callisto believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the Callisto Pharmaceuticals Annual Report on Form 10-K for the year ended December 31, 2006, and other periodic reports, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that products that appeared promi
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)...  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management ... and Regeneron will host an IR Thematic Conference Call on Alirocumab ... 2014 , Baird 2014 Healthcare Conference at 4:05 ... , Citi,s 9 th Annual Biotech Conference at ... , Morgan Stanley Global Healthcare Conference at 8:45 ...
(Date:8/19/2014)... Luoxis Diagnostics, Inc. , a ... MKT: AMPE), today announced an upcoming presentation at ... American Academy of Surgical Trauma (AAST) and Clinical ... Philadelphia, Pennsylvania that will be held ... from a recently completed five-year prospective clinical trial ...
(Date:8/19/2014)... ALBANY, New York , August 19, 2014 /PRNewswire/ ... " Surgical Navigation Systems Market (Neurosurgical Navigation Systems, ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 ... valued at USD 218.5 million in 2013 and is ... 2014 to 2020, to reach an estimated value of ...
Breaking Medicine Technology:Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 2Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 3Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 4Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 5Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 6Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 7Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 8Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 9
(Date:8/20/2014)... (PRWEB) August 20, 2014 Mixberry Media ... speech-enable their websites and create a new source of ... consume content by listening to a narration of their ... reader genders and languages. Users can now multitask: ... social networks, while consuming content. , Mixberry ...
(Date:8/20/2014)... Tappahannock, Va. (PRWEB) August 20, 2014 ... Dr. William Dameron , who joined its Warsaw Medical ... additional physician specialized in Family Medicine, is accepting new ... University School of Medicine, completed his residency at the ... relocating back to Virginia. , “I really like the ...
(Date:8/19/2014)... As moms and dads prepare their children to go ... normal routine of dropping their little ones off at daycare ... encourages them to use the opportunity to implement a ... Yarker explains, “Kids have small tummies, short attention spans, and ... food handouts, use snack time as another daily opportunity to ...
(Date:8/19/2014)... 2014 Crosley Law Firm, PC has reached ... against Lone Star Bakery for an undisclosed amount. The two ... and May of 2011, respectively. The injuries were caused by ... severe injury to the left hand of each man. , ... Bakery was short-staffed, having lost 200 of its, 500 workers ...
(Date:8/19/2014)... An editorial published in this week,s JAMA ... assessment tools when considering how to treat patients. Written ... Medical Center and chair of pediatrics at Boston University ... JAMA , the editorial examines results of a ... as an example of how doctors can often over-emphasize ...
Breaking Medicine News(10 mins):Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Riverside Warsaw Medical Arts’ Dr. William Dameron Accepting New Patients 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 3Health News:Crosley Law Firm Reaches Settlement for Hand Amputation Victims at Commercial Bakery 2Health News:Review of clinical treatment of bronchiolitis in infants reveals over-reliance on one test 2
... Rating ... , ... (PRWEB) March 23, 2010 -- The Hartville Group Inc., which provides pet health insurance ... Insurance, Hartville Pet Insurance, and the Petshealth Care Plan, has received an A+ rating ...
... ... ... Sir Richard Bowlby keynotes ,Linking Forces, educational event with 16-year history in community , ... , ...
... , March 23 InterMune, Inc. (Nasdaq: ... (MAA), submitted on March 2 seeking approval of ... adults, was validated by the European Medicines Agency (EMA). Validation ... is complete and that the review process will begin on ...
... ... for Haiti survivors. , ... (PRWEB) March 23, 2010 -- Just like any other business, non-profit organizations must ... VoiceNation,s call center agents and auto attendants assist to fill the ...
... ... sustainable solution to the crisis in Haiti. The flexibility of these products can easily make ... ... -- Bosoley Solar Energy’s line of solar lights brings vital illumination to residents and aid ...
... ... than first thought. , ... -- Long known for being an excellent source of fiber, two recent studies suggest that apples ... antioxidants, previous research has suggested that apples may prevent or reduce the risks of certain types ...
Cached Medicine News:Health News:Pet Insurance Provider Hartville Group Gets A+ Rating From Better Business Bureau 2Health News:Pet Insurance Provider Hartville Group Gets A+ Rating From Better Business Bureau 3Health News:Children's Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami 2Health News:Children's Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami 3Health News:Children's Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami 4Health News:Children's Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami 5Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 2Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 3Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 4Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 5Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 6Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 7Health News:VoiceNation Helps Non-Profits Gather Funding for Those in Need 2Health News:VoiceNation Helps Non-Profits Gather Funding for Those in Need 3Health News:Bosoley Solar Light Set to Bring Haiti Out of the Post-Earthquake Darkness 2Health News:Go with Your Gut and Boost your Immune System with America's Favorite Fruit 2Health News:Go with Your Gut and Boost your Immune System with America's Favorite Fruit 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: